Garrison Point Advisors LLC Sells 935 Shares of Johnson & Johnson $JNJ

Garrison Point Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,461 shares of the company’s stock after selling 935 shares during the period. Johnson & Johnson comprises about 1.2% of Garrison Point Advisors LLC’s portfolio, making the stock its 16th biggest position. Garrison Point Advisors LLC’s holdings in Johnson & Johnson were worth $2,667,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. GFG Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at approximately $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth $48,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the 1st quarter worth $52,000. Finally, Pandora Wealth Inc. acquired a new position in Johnson & Johnson during the 1st quarter worth about $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $186.50 on Friday. The company has a market capitalization of $449.34 billion, a PE ratio of 18.00, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The firm’s fifty day moving average is $184.25 and its 200 day moving average is $168.63. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Bank of America raised their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.